In a research note issued today, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Biogen (NASDAQ:BIIB) with a $386 price target, following last …
Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in today with his thoughts on Biogen Idec (NASDAQ:BIIB), following the results from a phase 2 study of …
In a research report released today, J.P.
In a research note issued today, J.P.
Cowen analyst Eric Schmidt maintained an Outperform rating on Biogen Idec (NASDAQ:BIIB) with a price target of $389, after the company reported positive interim …
